Related references
Note: Only part of the references are listed.Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?
Zhen Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells
Jia Z. Shen et al.
MOLECULAR CELL (2022)
Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis
Wei Shi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam-Artigues et al.
SCIENCE ADVANCES (2022)
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Jianzhang Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Huiyu Li et al.
CELL REPORTS MEDICINE (2022)
AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization
Tugce Batur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Design and Synthesis of 5-Aryl-substituted Phenylpyrimidine-2,4-diamine Derivatives as Novel Mer and Tyro3 Kinase Inhibitors
Yeonji Kim et al.
BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2021)
Patient-Derived Organoids as a Model for Cancer Drug Discovery
Colin Rae et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
Hefeng Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors
Satoshi Inoue et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
Dandan Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
Michael J. Bond et al.
RSC CHEMICAL BIOLOGY (2021)
Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor
Ho Jin Lee et al.
THERANOSTICS (2021)
Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker
Congjun Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
Olivier Zajac et al.
CELLS (2020)
AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network
Afnan Abu-Thuraia et al.
NATURE COMMUNICATIONS (2020)
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
Italia Falcone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
Markus Lauter et al.
CELL COMMUNICATION AND SIGNALING (2019)
Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
Feng Wang et al.
TRANSLATIONAL CANCER RESEARCH (2019)
Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET
Yingying Shen et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Qiuye Zhao et al.
CHEMICAL COMMUNICATIONS (2019)
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
Istvan Szabadkai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Marie-Anne Goyette et al.
CELL REPORTS (2018)
Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors
Min Jung Choi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
Xiaoxian Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Anexelekto /MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
Peter P. Ruvolo et al.
HAEMATOLOGICA (2017)
Anexelekto /MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
Peter P. Ruvolo et al.
HAEMATOLOGICA (2017)
AXL-Driven EMT State as a Targetable Conduit in Cancer
Jane Antony et al.
CANCER RESEARCH (2017)
Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors
Clemence Feneyrolles et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
Walter Keung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson et al.
NATURE CHEMICAL BIOLOGY (2015)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
Cyclin B1/Cdk1 Coordinates Mitochondrial Respiration for Cell-Cycle G2/M Progression
Zhaoqing Wang et al.
DEVELOPMENTAL CELL (2014)
Structural Elucidation of the DFG-Asp in and DFG-Asp out States of TAM Kinases and Insight into the Selectivity of Their Inhibitors
Abdellah Messoussi et al.
MOLECULES (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
Axl as a mediator of cellular growth and survival
Haley Axelrod et al.
ONCOTARGET (2014)
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Aaron S. Meyer et al.
SCIENCE SIGNALING (2013)
Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
Alexis Mollard et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Sacha J. Holland et al.
CANCER RESEARCH (2010)
Cdk2 Is Required for p53-Independent G2/M Checkpoint Control
Jon H. Chung et al.
PLOS GENETICS (2010)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
Chih-Chen Hong et al.
CANCER LETTERS (2008)
AXL is a potential target for therapeutic intervention in breast cancer progression
Yi-Xiang Zhang et al.
CANCER RESEARCH (2008)
TAM receptors are pleiotropic inhibitors of the innate immune response
Carla V. Rothlin et al.
CELL (2007)
Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinorna cells expressing AXL
Jong-Ding Lay et al.
CANCER RESEARCH (2007)
Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines
Lawrence L'Italien et al.
CELL CYCLE (2006)
Structural basis for Gas6-Axl signalling
T Sasaki et al.
EMBO JOURNAL (2006)
The activation of Akt/PKB signaling pathway and cell survival
G Song et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
Share Paper
